What does this research mean for the field?

Recent advances in the management of acute myeloid leukemia in older adults include the establishment of venetoclax-based regimens for intensive-chemotherapy-ineligible patients, updated risk stratification for less-intensive therapies, and the integration of targeted inhibitors, while TP53-mutated disease remains a critical unmet need. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To synthesize current evidence on risk stratification, genetic classification, and frontline and relapsed therapeutic approaches for adults aged 60 and older with acute myeloid leukemia.

September 3, 2026HematoOpen Access

Acute Myeloid Leukemia in Older Adults: A Comprehensive Narrative Review of Risk Stratification and Treatment Advances

View Full Paper

Ask AI

Bookmark

Authors

AMAhmed S. MohamedHackensack Meridian Health SDShraboni DeyHackensack University Medical Center SRShibhani RajannaHackensack Meridian Health

Discussion

Member takes

Implication

Narrative review reveals evolving risk stratification and targeted therapy advances in older adults with acute myeloid leukemia, highlighting expanded treatment options beyond intensive chemotherapy.

Key Points

To synthesize current evidence on risk stratification, genetic classification, and frontline and relapsed therapeutic approaches for adults aged 60 and older with acute myeloid leukemia.
Reviewed clinical trial evidence and consensus guidelines addressing older adults aged 60–75 years and those older than 75 years, including octogenarians.
Evaluated therapeutic modalities including intensive chemotherapy, lower-intensity venetoclax-based combinations, targeted small-molecule inhibitors, and reduced-intensity conditioning allogeneic stem cell transplantation.
In patients ineligible for intensive chemotherapy, venetoclax plus azacitidine demonstrated a composite complete remission rate of 66.4% and an improved median overall survival of 14.7 months compared to 9.6 months with azacitidine alone.
Randomized data in fit adults aged 60–75 indicate comparable therapeutic outcomes between intensive chemotherapy and venetoclax-based regimens, with potential advantages for venetoclax in adverse-risk disease.
Targeted inhibitors for FLT3, IDH1/2, and menin alongside updated 2024 ELN genetic risk classifications are refining lower-intensity regimens, though TP53-mutated disease remains a critical therapeutic challenge.

Cite This Study

Mohamed et al. (2026) studied this question.

synapsesocial.com/papers/6a993600636c6408cfa7eb99 https://doi.org/10.3390/hemato7030030

View Full Paper

Ask AI

Bookmark

Implication

Narrative review reveals evolving risk stratification and targeted therapy advances in older adults with acute myeloid leukemia, highlighting expanded treatment options beyond intensive chemotherapy.

Acute Myeloid Leukemia in Older Adults: A Comprehensive Narrative Review of Risk Stratification and Treatment Advances

Discussion

Member takes

Implication

Key Points

Cite This Study

Acute Myeloid Leukemia in Older Adults: A Comprehensive Narrative Review of Risk Stratification and Treatment Advances

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider